C4 Therapeutics rises on FDA nod to begin human study for lung cancer drug
05/07/2023 12:45
** Shares of drug developer C4 Therapeutics Inc CCCC.O up
5.7% at $ 2.99 before the bell
** Co says the U.S. Food and Drug Administration (FDA) has
cleared its investigational new drug (IND) application to begin
human study for lung cancer drug
** CCCC plans to test its drug candidate, CFT8919, as a
potential treatment for a type of non-small cell lung cancer
** Co says will begin clinical trial activities outside of
China after dose-escaltion activities are completed in ongoing
early-stage study in China
** As of last close, CCCC shares down 52% YTD
(Reporting by Rupali Chaudhary in Bengaluru)
((Rupali.chaudhary@thomsonreuters.com))